

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

04 FEB 10 PM 3:23

00000452354

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name <u>Ricchetti Incorporated</u>			
2. Address <input type="checkbox"/> Check if different than previously reported <u>1001 G Street NW Suite 700 EAST</u>			
3. Principal Place of Business (if different from line 2) City: <u>Washington</u> State/Zip (or Country) <u>DC 20001</u>			
4. Contact Name <u>Jay Heimbsch</u>	Telephone <u>(202) 879-9367</u>	E-mail (optional)	5. Senate ID # <u>62778-</u>
7. Client Name <input type="checkbox"/> Self <u>Novartis</u>			6. House ID # <u>353950</u>

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30)  OR Year End (July 1-Dec)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_

11. No Lobbying

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ <u>\$60,000<sup>00</sup></u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6011 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
---	---

Signature \_\_\_\_\_

Printed Name and Title James Heimbruch Vice President

LD-2 (REV. 6/98)

000000  
2355

Registrant Name Ricchetti Inc. Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare prescription drug benefits  
HR 1 - Medicare Prescription Drug and Modernization Act of 2003  
S 1 - Prescription Drug and Medicare Improvement Act of 2003

All aspects of above legislation as they affect pharmaceutical including coverage, costs and access provisions.

17. House(s) of Congress and Federal agencies contacted  Check if None

US Senate  
US House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Steve Ricchetti	
Jeff Ricchetti	
Lisa Kountoupas	
James Heimbach	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Novartis is owned by Novartis AG, Basel Switzerland

Signature \_\_\_\_\_

Printed Name and Title James T. Heimbech Vice President

Form LD-2 (Rev. 6/98)

000000  
2356

Registrant Name Ricchetti Inc. Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each information as requested. Attach additional page(s) as needed.

15. General issue area code HR (one per page)

16. Specific lobbying issues

Generic drug availability  
S.54 - Greater Access to Affordable Pharmaceuticals Act

Issues pertaining to generic pharmaceuticals and the impact on pharmaceutical companies.

HR 2218 - Providing for regulation of contact lenses as medical device  
17. House(s) of Congress and Federal agencies contacted  Check if None

US Senate

US House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Steve Ricchetti	
Jeff Ricchetti	
Lisa Kountoupas	
James Heimbrich	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Novartis is owned by Novartis AG Basel Switzerland

Signature \_\_\_\_\_

Printed Name and Title James T. Heimbech Vice President

Form LD-2 (Rev. 6/98)

Registrant Name Ricchetti Incorporated Client Name Novartis

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each of information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Reimportation of Prescription Drugs  
HR 2427 - Pharmaceutical Market Access Act of 2003

All issues pertaining to regulations for the reimportation of prescription drugs into the United States

17. House(s) of Congress and Federal agencies contacted  Check if None

US House  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Steve Ricchetti	
Jeff Ricchetti	
Lisa Kountoupas	
James Helmreich	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Novartis is owned by Novartis AG Basel Switzerland

Signature \_\_\_\_\_

Date \_\_\_\_\_

Printed Name and Title

James Hembach

Vice President

Form LD-2 (Rev. 6/98)

Pa



Registrant Name Ricchetti Incorporated Client Name Novartis

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which it engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each of information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicaid Reform

Issues pertaining to the President's proposed reform of Medicaid

17. House(s) of Congress and Federal agencies contacted

Check if None

US House

US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Steve Ricchetti	
Jeff Ricchetti	
Lisa Kountoupas	
James Heimlich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Novartis is owned by Novartis AG Basel Switzerland

Signature \_\_\_\_\_

Date \_\_\_\_\_

Printed Name and Title

James Hembach

Vice President

Form LD-2 (Rev. 6/98)

Pa

Registrant Name Ricchetti Incorporated Client Name Novartis

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which it engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each of information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Oral cancer pharmaceuticals

S 1037  
HR 1288 } Access to Cancer Therapies Act of 2003

Issues pertaining to coverage for oral cancer therapies

17. House(s) of Congress and Federal agencies contacted  Check if None

US House  
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Steve Ricchetti</u>	
<u>Jeff Ricchetti</u>	
<u>Lisa Kountoupas</u>	
<u>James Humbach</u>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Novartis is owned by Novartis AG Basel Switzerland

Signature \_\_\_\_\_

Printed Name and Title James Hembach Vice President

Form LD-2 (Rev. 6/98)